Jesper Brandgaard ny formand for LEO Pharmas bestyrelse
1.7.2021 13:00:00 CEST | LEO Pharma | Pressemeddelelse

LEO Fondet har udpeget Jesper Brandgaard som ny formand for LEO Pharmas bestyrelse. Han afløser Olivier Bohuon, der i maj valgte at forlade formandsposten. Jesper Brandgaard overtager formandsposten den 1. august 2021.
”Det glæder mig meget, at Jesper Brandgaard har sagt ja til at være formand for LEO Pharmas bestyrelse. Jesper kommer med omfattende ekspertise og erfaring fra medicinalindustrien og har skabt markante resultater gennem sine 20 år i Novo Nordisk, heraf 17 år som CFO, hvor han spillede en nøglerolle i virksomhedens globale vækst og succes. Samtidig kommer han med solid erfaring fra bestyrelsesposter i en række både børsnoterede og ikke-børsnoterede virksomheder samt indgående kendskab til den danske fondsejerskabsmodel. Der er ingen tvivl om, at Jespers betydelige erfaring og viden indenfor medicinalindustrien, hans integritet og brede forretningsforståelse vil være et stort aktiv, der kan understøtte LEO Pharmas ambitiøse vækststrategi de kommende år,” siger Lars Olsen, formand for LEO Fondets bestyrelse.
Jesper Brandgaard overtager formandsposten den 1. august 2021.
”LEO Pharma er et unikt selskab med en stærk platform inden for hudsygdomme – og et stort potentiale. Det er et privilegium at blive en del af LEO Pharmas rejse mod globalt lederskab inden for dermatologi, og jeg ser meget frem til at bidrage til realiseringen af LEO Pharmas ambitioner,” siger Jesper Brandgaard.
Jesper Brandgaard har en kandidatgrad i økonomi og revision samt en MBA, begge fra Copenhagen Business School. I 1999 blev han ansat som Senior Vice President for Corporate Finance i Novo Nordisk A/S og blev udnævnt til CFO i 2000. Han forlod Novo Nordisk i 2019 for at forfølge en karriere som professionelt bestyrelsesmedlem. Han er medlem af flere bestyrelser, herunder næstformand for Chr. Hansen Holding, næstformand for William Demant Invest, bestyrelsesmedlem i William Demant Fonden, medlem af Komitéen for god Selskabsledelse og medlem af Vækstpartner Kapitals advisory board.
Kontakter
Signe Krabek, Head of Communication and Public Affairs
Tlf: +45 20 49 68 69
E-mail: signe.krabek@leo-foundation.org
Billeder
Information om LEO Pharma
Om LEO Fondet
LEO Fondet er en af Danmarks største erhvervsdrivende fonde og engageret ejer af medicinalvirksomheden LEO Pharma. Fondet har som primært formål at sikre virksomhedens langsigtede udvikling og succes som en global leder inden for dermatologi, der leverer konkurrencedygtige resultater.
Udover ejerskabet af LEO Pharma uddeler Fondet filantropisk støtte til international forskning i hud og hudsygdomme og arbejder for at gøre Danmark til et globalt fyrtårn inden for hudforskning.
LEO Fondet har en formue på ca. DKK 16 mia. Afkast fra investering af formuen skal sikre evnen til at understøtte LEO Pharmas langsigtede udvikling samt Fondets filantropiske aktiviteter.
Om LEO Pharma
LEO Pharma er en globalt førende virksomhed inden for medicinsk dermatologi. Virksomheden har en robust pipeline og tilbyder en bred vifte af behandlinger og behandlingstyper. LEO Pharma blev dannet i 1908 som Danmarks første medicinalvirksomhed – og med en høj innovationsgrad har man i årtier drevet forskning og udvikling for at kunne tilbyde nye innovative behandlinger til patienter med hudsygdomme. LEO Pharma har hovedsæde i Danmark og har 6.000 ansatte. Virksomhedens behandlinger sælges i 130 lande og hjælper hvert år mere end 93 millioner patienter.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma delivers 11% revenue growth at CER and achieves strategic milestones16.11.2026 10:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 16 November, 2026 - In 9M 2026, LEO Pharma delivered strong innovation-led growth, with a significantly improved gross margin and continued investment in innovation. In September, LEO Pharma completed the acquisition of dersimelagon, an investigational first-in-class oral therapy now under FDA Priority Review, marking an important strategic milestone. Momentum continued after the period, with new approvals for Anzupgo® in Europe and China, further extending the product’s reach and underscoring LEO Pharma’s commitment to advancing innovation in dermatology. Financial highlights LEO Pharma’s revenue increased by 9% to DKK 10,961 million for 9M 2026, and by 11% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) with Rest of World (10% at CER) and Europe (1% at CER) also contributing. Revenue from the Dermatology portfolio grew by 13% (CER), driven by the Innovative brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had
LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China13.11.2026 08:00:00 CET | Pressemeddelelse
Anzupgo® (delgocitinib) cream has been approved by China’s National Medical Products Administration (NMPA) for adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate. The approval is supported by positive results from the DELTA China phase 3 trial, together with the broader delgocitinib clinical program, including DELTA 1, DELTA 2, DELTA 3 and DELTA Force.1-7 The approval reflects LEO Pharma’s commitment to improving care for adults living with moderate to severe chronic hand eczema in China, an exciting and important market for the company.
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse
Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse
New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum

